IAPs associated cell cycle proteins, compositions and...

Details IAPs associated cell cycle proteins, compositions and... IAPs associated cell cycle proteins, compositions and...

1999-11-17

2004-05-18

Ungar, Susan (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S006120, C435S007100, C435S069100, C436S501000, C436S543000

Reexamination Certificate

active

06737232

ABSTRACT:

FIELD OF THE INVENTION
The present invention is directed to compositions involved in cell cycle regulation and methods of use. More particularly, the present invention is directed to genes encoding proteins and proteins involved in cell cycle regulation. Methods of use include use in assays screening for modulators of the cell cycle and use as therapeutics.
BACKGROUND OF THE INVENTION
Cells cycle through various stages of growth, starting with the M phase, where mitosis and cytoplasmic division (cytokinesis) occurs. The M phase is followed by the G1 phase, in which the cells resume a high rate of biosynthesis and growth. The S phase begins with DNA synthesis, and ends when the DNA content of the nucleus has doubled. The cell then enters G2 phase, which ends when mitosis starts, signaled by the appearance of condensed chromosomes. Terminally differentiated cells are arrested in the G1 phase, and no longer undergo cell division.
The hallmark of a malignant cell is uncontrolled proliferation. This phenotype is acquired through the accumulation of gene mutations, the majority of which promote passage through the cell cycle. Cancer cells ignore growth regulatory signals and remain committed to cell division. Classic oncogenes, such as ras, lead to inappropriate transition from G1 to S phase of the cell cycle, mimicking proliferative extracellular signals. Cell cycle checkpoint controls ensure faithful replication and segregation of the genome. The loss of cell cycle checkpoint control results in genomic instability, greatly accelerating the accumulation of mutations which drive malignant transformation. Thus, modulating cell cycle checkpoint pathways and other such pathways with therapeutic agents could exploit the differences between normal and tumor cells, both improving the selectivity of radio- and chemotherapy, and leading to novel cancer treatments. As another example, it would be useful to control entry into apoptosis.
On the other hand, it is also sometimes desirable to enhance proliferation of cells in a controlled manner. For example, proliferation of cells is useful in wound healing and where growth of tissue is desirable. Thus, identifying modulators which promote, enhance or deter the inhibition of proliferation is desirable.
Despite the desirability of identifying cell cycle components and modulators, there is a deficit in the field of such compounds. Accordingly, it would be advantageous to provide compositions and methods useful in screening for modulators of the cell cycle. It would also be advantageous to provide novel compositions which are involved in the cell cycle.
SUMMARY OF THE INVENTION
The present invention provides cell cycle proteins and nucleic acids which encode such proteins. Also provided are methods for screening for a bioactive agent capable of modulating the cell cycle. The method comprises combining a cell cycle protein and a candidate bioactive agent and a cell or a population of cells, and determining the effect on the cell in the presence and absence of the candidate agent. Therapeutics for regulating or modulating the cell cycle are also provided.
In one aspect, a recombinant nucleic acid encoding a cell cycle protein of the present invention comprises a nucleic acid that hybridizes under high stringency conditions to a sequence complementary to that set forth in
FIG. 1
,
3
,
5
,
7
, or
9
(SEQ ID Nos. 1, 3, 5, 7, and 9). In a preferred embodiment, the cell cycle protein provided herein binds to at least one inhibitor of apoptosis proteins (IAPs).
In one embodiment, a recombinant nucleic acid is provided which comprises a nucleic acid sequence as set forth in
FIG. 1
,
3
,
5
,
7
, or
9
(SEQ ID Nos. 1, 2, 3, 5, 7, and 9). In another embodiment, a recombinant nucleic acid encoding a cell cycle protein is provided which comprises a nucleic acid sequence having at least 85% sequence identity to a sequence as set forth in
FIG. 1
,
3
,
5
,
7
or
9
(SEQ ID Nos. 1, 3, 5, 7, and 9). In a further embodiment, provided herein is a recombinant nucleic acid encoding an amino acid sequence as depicted in
FIG. 2
,
4
,
6
,
8
, or
10
(SEQ ID Nos. 2, 4, 6, 8, and 10).
In another aspect of the invention, expression vectors are provided. The expression vectors comprise one or more of the recombinant nucleic acids provided herein operably linked to regulatory sequences recognized by a host cell transformed with the nucleic acid. Further provided herein are host cells comprising the vectors and recombinant nucleic acids provided herein. Moreover, provided herein are processes for producing a cell cycle protein comprising culturing a host cell as described herein under conditions suitable for expression of the cell cycle protein. In one embodiment, the process includes recovering the cell cycle protein.
Also provided herein are recombinant cell cycle proteins encoded by the nucleic acids of the present invention. In one aspect, a recombinant polypeptide is provided herein which comprises an amino acid sequence having at least 80% sequence identity with a sequence as set forth in
FIG. 2
,
4
,
6
,
8
, or
10
(SEQ ID Nos. 2, 4, 6, 8, and 10). In one embodiment, a recombinant cell cycle protein is provided which comprises an amino acid sequence as set forth in
FIG. 2
,
4
,
6
,
8
, or
10
(SEQ ID Nos. 2, 4, 6, 8, and 10).
In another aspect, the present invention provides isolated polypeptides which specifically bind to a cell cycle protein as described herein. Examples of such isolated polypeptides include antibodies. Such an antibody can be a monoclonal antibody. In one embodiment, such an antibody reduces or eliminates the biological function of said cell cycle protein.
Further provided herein are methods for screening for a bioactive agent capable of binding to a cell cycle protein. In one embodiment the method comprises combining a cell cycle protein and a candidate bioactive agent, and determining the binding of said candidate bioactive agent to said cell cycle protein.
In another aspect, provided herein is a method for screening for a bioactive agent capable of interfering with the binding of a cell cycle protein and an IAPs. In one embodiment, such a method comprises combining a cell cycle protein, a candidate bioactive agent and an IAPs, and determining the binding of the cell cycle protein and the IAPs. If desired, the cell cycle protein and the IAPs can be combined first.
Further provided herein are methods for screening for a bioactive agent capable of modulating the activity of cell cycle protein. In one embodiment the method comprises adding a candidate bioactive agent to a cell comprising a recombinant nucleic acid encoding a cell cycle protein, and determining the effect of the candidate bioactive agent on the cell. In a preferred embodiment, a library of candidate bioactive agents is added to a plurality of cells comprising a recombinant nucleic acid encoding a cell cycle protein.
Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.


REFERENCES:
patent: 5750344 (1998-05-01), Doyle
patent: 6066474 (2000-05-01), Marcu
Lazar et al., Molecular and Cellular Biology, vol. 8, No. 3, pp. 1247-1252, 1988.*
Burgess et al., The Journal of Cell Biology, vol. 111, pp. 2129-2138, Nov. 1990.*
Bowie et al., Science, vol. 247, pp. 1306-1310, Mar. 1990.*
Bork, Genome Research, vol. 10, pp. 398-400, 2000.*
Jayawickreme et al., Current Opinion in Biotechnology, vol. 8, pp. 629-634, 1997.*
McCarthy et al., “Apoptosis induced by Drosophila reaper and grim in a human system. Attenuation by inhibitor of apoptosis proteins (cIAPs),”J. Biol. Chem., 273(37):24009-24015 (1998).
Helbing et al., “A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis,”Cancer Res., 57(7):1255-1258 (1997).
Garkavstev et al., “Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation,”Nat. Genet., 14(4):415-420.
Garkavstev et al., “The candidate tomour suppressor p33ING1 cooperates with p53 in cell growth control,”Nature, 391(6664):295-298 (1998).

Affiliated with

Also associated with

Rating

IAPs associated cell cycle proteins, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IAPs associated cell cycle proteins, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IAPs associated cell cycle proteins, compositions and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3253225